GSAT Volume Alert - GSAT 2.58 Globalstar $GSAT Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
GSAT Volume Alert - GSAT 2.58 Globalstar $GSAT Hit a high of 2.70 Currently 11:14 Last price 2.58 -0.05 -1.90% With a day low of 2.56 and a current volume of 1,781,952.

GSAT Globalstar Recent Headline News

InsiderInsights.com Daily Round Up 11/10/14: CHK, TWX, SGEN, PBFX
InsiderInsights - at Seeking Alpha - Tue Nov 11, 2:29AM CST

HAS: 56.83 (-0.25), VR: 39.74 (-0.05), SEIC: 39.35 (-0.13), DRNA: 9.52 (+0.24), HA: 18.23 (-0.26), SAM: 264.37 (-1.70), PBFX: 25.38 (-0.07), AMRI: 17.49 (+0.39), GSAT: 2.61 (-0.02), TNET: 31.44 (+0.55), TWX: 77.94 (+0.61), HLT: 25.17 (+0.03), Q: 56.69 (-0.53), SGEN: 36.95 (+0.05), CF: 267.65 (+13.25), OPK: 8.49 (-0.14), CHK: 23.56 (+0.66), CNDO: 1.73 (+0.21), CO: 4.96 (+0.04), CPLA: 68.77 (-0.40)

Globalstar: Evaluating Bankruptcy Risk
Richard Pearson - Seeking Alpha - Mon Nov 10, 8:30AM CST
Shares of Globalstar (NYSEMKT: GSAT ) have been on a roller coaster ride ever since Kerrisdale Capital presented a short thesis on the company in early October. The shares fell from just under $4.00 to as low as $1.56, before rebounding to the...
GSAT: 2.61 (-0.02)

Globalstar service revenue grows during past 3, 9 months
M2 - Mon Nov 10, 7:51AM CST
Globalstar, Inc. (NYSE: GSAT) today announced its financial results for the three- and nine-month periods ended September 30, 2014.
GSAT: 2.61 (-0.02)

WSJ: Elon Musk thinking of launching 700 Web satellites
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 1:12PM CST

LORL: 76.39 (-0.69), IRDM: 9.94 (-0.01), I: 18.06 (-0.16), GSAT: 2.61 (-0.02), VSAT: 62.73 (-0.28)

Globalstar's (GSAT) CEO Jay Monroe on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sat Nov 08, 6:37AM CST

GSAT: 2.61 (-0.02)

Globalstar closes up 5.7% following Q3 report
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:04PM CST

GSAT: 2.61 (-0.02)

Globalstar Announces Third Quarter 2014 Results
GlobeNewswire - Thu Nov 06, 4:24PM CST
Globalstar, Inc. (NYSE MKT:GSAT) today announced its financial results for the three and nine month periods ended September 30, 2014.
GSAT: 2.61 (-0.02)

Globalstar beats by $0.14, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 4:02PM CST

GSAT: 2.61 (-0.02)

After Recent Spike, Straight Path Could Fall 50%
Richard Pearson - Seeking Alpha - Tue Nov 04, 8:30AM CST
The recent travails of Globalstar Inc. (NYSEMKT: GSAT ) serve well to illustrate how retail-oriented stock promotions can achieve wildly overvalued share prices, until they are found out and come crashing back to earth. Prior to a report from...
IDT: 17.67 (+0.04), GNE: 6.65 (-0.04), STRP: 17.69 (-0.67), GSAT: 2.61 (-0.02)

Globalstar, Inc. Third Quarter 2014 Earnings Call Release Notice
GlobeNewswire - Mon Nov 03, 3:05PM CST
Globalstar, Inc. (NYSE MKT:GSAT) will announce its third quarter 2014 financial results on Thursday, November 6, 2014 after the market's close. The Company will conduct an earnings conference call that evening at 5:00 p.m. Eastern Time to discuss third quarter 2014 results.
GSAT: 2.61 (-0.02)

XNPT, AMRS, GSAT, CRDC, IOSP, OKS Expected To Be Down After Next Earnings Releases
M2 - Mon Nov 03, 3:33AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Tuesday, November 4th 2014 and determining how the stocks have performed After their last 12 quarterly, 6 quarterly and December earnings reports. Xenoport Inc (NASDAQ:XNPT), AMYRIS INC (NASDAQ:AMRS), Globalstar Inc (OTC:GSAT), Cardica Inc (NASDAQ:CRDC), INNOSPEC INC. (NASDAQ:IOSP), ONEOK PARTNERS, L.P. (NYSE:OKS) are all expected to be Down After their earnings are released. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php . The following stocks are expected to go Down After earnings are released Tuesday:
AMRS: 2.85 (-0.19), IOSP: 43.82 (-0.24), OKE: 56.39 (+0.20), CRDC: 0.86 (-0.05), OKS: 47.66 (-0.40), GSAT: 2.61 (-0.02), XNPT: 7.70 (+0.15)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 4:39PM CDT

FRM: 6.49 (+0.04), TTMI: 6.90 (+0.05), EGO: 5.89 (+0.59), AMBR: 11.05 (-0.40), BDBD: 9.12 (-0.13), DUST: 32.92 (-6.96), BZH: 19.52 (+0.53), ARNA: 4.51 (+0.11), GSAT: 2.61 (-0.02), CTCT: 35.62 (+0.01)

Globalstar: Elements Of Promotion
Richard Pearson - Seeking Alpha - Thu Oct 30, 9:00AM CDT
A few weeks ago, Kerrisdale Capital gave a presentation delivering its short thesis on Globalstar Inc. (NYSEMKT: GSAT ). Prior to rumors of Kerrisdale's presentation , Globalstar had been trading at close to $4.00, with a market cap of nearly $4...
NEON: 2.25 (unch), UNXL: 5.47 (+0.04), GSAT: 2.61 (-0.02)

Alternative Carriers Stocks Under Review - tw telecom, Vonage Holdings, Globalstar, Level 3 Communications, and 8x8
PR Newswire - Wed Oct 29, 8:20AM CDT
Investor-Edge has initiated coverage on the following equities: tw telecom inc. (NASDAQ: TWTC), Vonage Holdings Corporation (NYSE: VG), Globalstar Inc. (NYSE MKT: GSAT), Level 3 Communications Inc. (NYSE: LVLT), and 8x8 Inc. (NASDAQ: EGHT). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Tuesday, October 28, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,005.75, up 1.12% and the NASDAQ Composite closed at 4,564.29, up 1.75%. The S&P 500 finished the session 1.19% higher at 1,985.05. During the trading session, all the ten sectors finished on a higher note. The S&P 500 Telecommunication Services Sector Index ended the day at 159.20, up 0.95%, with the index advancing 2.82% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
LVLT: 46.48 (+0.19), TWTC: 42.78 (+1.01), GSAT: 2.61 (-0.02), EGHT: 8.01 (+0.07), VG: 3.75 (+0.15)

Globalstar: A Review Of The Experimental Licenses For TLPS
Kerrisdale Capital Management - Seeking Alpha - Tue Oct 28, 8:00AM CDT
Recently, Globalstar Inc. (NYSEMKT: GSAT ) applied to the FCC for a new experimental license to test its Terrestrial Low Power Service (TLPS) concept in California. Though the initial irrational enthusiasm over this relatively unimportant piece of...
GSAT: 2.61 (-0.02)

Ontario Federation of Snowmobile Clubs (OFSC) Selects Globalstar GPS Satellite Technology for Groomer Fleet Tracking
Marketwire Canada - Wed Oct 22, 7:00AM CDT
Editors Note: There is a photo associated with this press release.
GSAT: 2.61 (-0.02)

Globalstar Reiterates Value of Spectrum Assets
GlobeNewswire - Mon Oct 20, 4:48PM CDT
Globalstar, Inc. (NYSE:GSAT) today issued the following statement in response to Kerrisdale Capital's latest misguided attempt to manipulate the Company's stock price:
GSAT: 2.61 (-0.02)

Entravision Communications Corporation: My Additional Take
Paulo Santos - at Seeking Alpha - Thu Oct 16, 9:55AM CDT

EVC: 5.18 (+0.04), GSAT: 2.61 (-0.02)

Why Globalstar (GSAT) Stock Is Slipping Today
at The Street - Mon Oct 13, 2:38PM CDT
Globalstar (GSAT) stock is falling in late afternoon trading following another move by short seller Kerrisdale Capital.
GSAT: 2.61 (-0.02)

Globalstar Responds to Kerrisdale Capital's FCC Filing
GlobeNewswire - Mon Oct 13, 1:23PM CDT
Globalstar, Inc. (NYSE MKT:GSAT) issued the following statement in response to Kerrisdale Capital's ("Kerrisdale" recent filing with the Federal Communications Commission ("FCC" :
GSAT: 2.61 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 230

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 225

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
DIRECTV Bags New NHL Deals: Stakes for Sports Fans

Updated Category News Views 308

NHL Fans, Strap in: DIRECTV Expands Its Lineup In a world where keeping up with your favorite team gets tougher each day, DIRECTV just lobbed a puck right into the net with their latest play. They've snagged a multi-year deal with the NHL for the Carolina Hurricanes, Columbus Blue Jackets, Minnesota Wild, and St. Louis Blues networks. It's a game changer, folks. If you...

Continue Reading
Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

Updated Category News Views 412

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Continue Reading
Firefox Champions Privacy with Iconic Internet Campaign

Updated Category News Views 106

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Continue Reading
Innovent's IBI354: New Data Spurs Hope for HER2+ BC

Updated Category News Views 130

Innovent Lauds HER2 ADC's Moment at ESMO 2026 Alright, chin up, investors. At the 2026 ESMO Congress, Innovent's throwing down some promising Phase 2 data for their brainchild, IBI354. You hear that name and it's like hearing about a rock star in the making in the oncology world. The potential here isn’t just talk—it's a loud, resounding call for attention. Their...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 288

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 131

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 127

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 134

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading

Top 5 Most Recently Viewed Articles

Expanding Horizons: Future of IVD Contract Manufacturing

Updated Category News Views 117

The Growing Landscape of IVD Contract Manufacturing The in vitro diagnostics (IVD) contract manufacturing market is on the brink of significant expansion, anticipated to reach a staggering USD 39.74 billion by 2031. This growth represents a compounded annual growth rate (CAGR) of 11.60% from 2024 to 2031, driven chiefly by the needs of the healthcare industry to keep pace...

Continue Reading
Citi Upgrades AerCap Holdings Price Target to $117 Amid Strong Performance

Updated Category News Views 79

Citi Upgrades AerCap Holdings Price Target Citi has recently updated its outlook on AerCap Holdings (NYSE:AER), raising the price target to $117 from $113. This move reflects Citi's confident stance on the aircraft leasing company's financial health within the aviation sector. By reaffirming their buy rating, the firm signals strong expectations for AerCap's growth...

Continue Reading
LG Energy Solution Reports Strong Q2 2025 Financial Performance

Updated Category News Views 750

LG Energy Solution Achieves Remarkable Financial Milestones In a significant announcement, LG Energy Solution has revealed its performance for the second quarter of 2025, detailing impressive results that demonstrate the company's resilience and strategic focus on growth. With consolidated revenue of KRW 5.6 trillion and an operating profit of KRW 492.2 billion, the...

Continue Reading
Genpact Shines as a Leader in Sustainability Recognition

Updated Category News Views 264

Genpact's Sustainable Initiatives Gain Global Recognition Recently, Genpact (NYSE: G), an advanced technology services provider, received significant acclaim for its commitment to sustainability. Being featured in TIME's prestigious list of the World's Best Companies in Sustainable Growth for 2025 showcases their dedication to ethical business practices and innovation. A...

Continue Reading
Medical Express Ambulance Faces Data Breach Investigation

Updated Category News Views 344

Understanding the Data Breach Investigation Edelson Lechtzin LLP, a prominent class action law firm, is currently looking into data privacy concerns affecting customers of Medical Express Ambulance, Inc. (MedEx). MedEx has reported potential unauthorized access to its network, raising significant alarm regarding the safety of customer data. Medical Express Ambulance, Inc....

Continue Reading